For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Given the probability of trial success and current valuation, we rate the ATYR stock 'Hold' as risk and reward appear ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the ...

A phase II study has revealed that combining the JAK inhibitor tofacitinib (Xeljanz) with the investigational drug ...

The VIASKIN peanut patch (VP250) is safe and effective for children aged 1 to 3 years who have peanut allergy, with and without atopic comorbidities.

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not ...

Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's ...